• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Oncology
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Supply Chain
    • AI and Machine Learning
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Oncology
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Supply Chain
    • AI and Machine Learning
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Pharma

A chessboard with blocks that read MA
Pharma

Supernus-Indivior merger is about scale, business development

Supernus and Indivior have agreed to a merger, forming a new CNS-focused biopharma, which will generate an expected $2.2B in sales this year.
Kevin Dunleavy Aug 3, 2026 11:20am
Data security and privacy concept

Amgen says patient data, IP stolen in cybersecurity breach

Aug 3, 2026 11:05am
lifesciencetoplinepodcastheroimagenoblepng

Inside Noble’s connected approach to patient support

Brought to you by NOBLE, Inc
Law Legal System Justice Crime concept Mallet Gavel Hammer and Scales on tabl

Sandoz inks dual settlements to resolve most US antitrust claims

Aug 3, 2026 10:18am
Why the Real Risk in Hub Transition is Inertia

What Hub Transitions Really Cost Manufacturers

Brought to you by Gifthealth
Graphic image of two hands shaking with employeesexecutives on the forearms of each shaking hand

Gerresheimer sheds pair of units in deal valued at €1.5B

Aug 3, 2026 9:40am
Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings